Elevated circulating lactate in late-stage melanoma patients
Clicks: 1
ID: 320149
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #104 of 111 articles by views in qjm : monthly journal of the association of physicians
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Highly glycolytic, "Warburg-like" tumors consume high concentrations of glucose and excrete similarly high levels of lactate to meet the excessive energy demands of rapidly proliferating cells. Historically, this has been viewed as an energy inefficient process that results in a metabolic waste product which provides little to no benefit to a growing tumor. However, several studies now cumulatively demonstrate that extracellular lactate provides important pro-tumorigenic, pro-metastatic and immune evasive contributions due to its ability to serve as an alternative metabolic substrate and/or a direct histone modifier. AIM: To investigate whether late-stage cancer patients have elevated circulating lactate levels and if it correlates to immunotherapy responsiveness. DESIGN: We assayed retrospective and prospective melanoma patient plasmas for plasma metabolites and then stratified to therapeutic responses and correlations to circulating immune cell determinants. METHODS: 38 chemotherapy/immunotherapy naïve, stage III/IV melanoma patient plasmas-and 10 normal control plasmas-were assayed by kit for circulating lactate, pyruvate, glucose and LDH and then correlated to all therapy and immunotherapy responses. RESULTS: Circulating plasma lactate is elevated in late-stage melanoma patients and statistically correlates with a higher percentage of immune checkpoint blockade (ICB) non-responsiveness and fewer circulating activated CD8+ T cells. Our data additionally show that circulating pyruvate is elevated in late-stage melanoma patient plasmas, strongly correlates with increased circulating lactate and is predictive of ICB non-responsiveness. CONCLUSIONS: These studies are in line with previous mouse studies linking elevated lactate to immune evasion processes arising from tumor growth and progression.
| Reference Key |
openalex_W7167711158
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Beatriz E. Rendon, Jun Yan, Hong Li, Jordan T. Noe, Zhongbin Deng, Melissa Hall, Maiying Kong, Jason Chesney, Robert A. Mitchell |
| Journal | qjm : monthly journal of the association of physicians |
| Year | 2026 |
| DOI |
10.1093/qjmed/hcag179
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.